Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Written by Customer Service on December 5, 2020. Posted in Public Companies.

Data support novel approach to develop and manufacture a best-in-class, durable medicine for people living with hemoglobinopathiesIND filing for EDIT-301 planned by end of 2020CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced preclinical data and successful development of a large-scale manufacturing process for EDIT-301, a potentially best-in-class, one-time, durable, autologous cell therapy medicine to treat sickle cell disease and beta-thalassemia. EDIT-301 is the first experimental medicine in development generated using CRISPR/Cas12a gene editing. The Company reported these data today at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH) being held virtually.The data showed that high levels of editing in CD34+...

Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

Written by Customer Service on December 5, 2020. Posted in Public Companies.

CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that preclinical data with FTX-6058 for the treatment of sickle cell disease will be presented in three posters at the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 5-8, 2020. FTX-6058 is a highly potent small molecule EED inhibitor that induces expression of fetal hemoglobin (HbF). Elevating HbF can compensate for the mutated adult hemoglobin that has been identified as the root cause of several hemoglobinopathies and can ameliorate or eliminate the symptoms of sickle cell disease.“We are encouraged by the robust preclinical data package and...

Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas

Written by Customer Service on December 5, 2020. Posted in Public Companies.

Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1Longer-term median follow-up of 40 months from the JULIET study showed a 33% two-year progression-free survival rate in patients with r/r DLBCL2Both ELARA and JULIET trials reaffirm safety profile of Kymriah with no new short- or long-term safety signals identifiedBasel, December 5, 2020 — Novartis announced analyses from two separate trials with Kymriah® (tisagenlecleucel) in patients with certain advanced lymphomas. In the interim analysis of the investigational Phase II ELARA study, Kymriah led to a complete response (CR) in 65% of patients with relapsed or refractory (r/r) follicular lymphoma (FL) and an overall response rate (ORR) of 83%...

Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020

Written by Customer Service on December 5, 2020. Posted in Public Companies.

BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed; Will Support Planned IND Submission in the Second Half of 2021In Vivo Data from Makassar Base Editing Program Demonstrate Long-term Engraftment and Editing Retention at 16 WeeksCAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that updated data from the company’s complementary base editing approaches to treat hemoglobinopathies are being presented during poster sessions at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020). The meeting is being held virtually December 5-8, 2020.“Base editing is ideally suited to precisely edit the genetic mutations that cause disease without disrupting...

Mitteilung | MCH Group | Kapitalerhöhung

Written by Customer Service on December 5, 2020. Posted in Public Companies.

Abschluss der Bezugsrechtsemission für die erste Tranche der KapitalerhöhungenDie ausserordentliche Generalversammlung der MCH Group AG hat am 27. November 2020 unter anderem beschlossen, Kapitalerhöhungen im Umfang von bis zu CHF 104.5 Mio. in zwei Tranchen durchzuführen. In der ersten Tranche wird das Aktienkapital der Gesellschaft durch die Ausgabe von 2’000’000 neuen Namenaktien mit einem Nennwert von je CHF 10.00 zum Ausgabebetrag von je CHF 15.00 von bisher CHF 60’065’750 auf neu CHF 80’065’750 erhöht. Die Bezugsfrist für diese erste Tranche der beschlossenen Kapitalerhöhungen dauerte vom 30. November bis 4. Dezember 2020, 12.00 Uhr (MEZ).Für jede am 27. November 2020 nach Handelsschluss gehaltene MCH-Aktie wurde in dieser ersten Tranche ein Bezugsrecht zugeteilt. Drei Bezugsrechte berechtigten...

Communiqué | MCH Group | Augmentation de capital

Written by Customer Service on December 5, 2020. Posted in Public Companies.

Clôture de l’émission de droits de souscription pour la première tranche des augmentations de capitalL’assemblée générale extraordinaire de MCH Group SA du 27 novembre 2020 a, entre autres, décidé de réaliser des augmentations de capital d’un montant maximum de 104,5 millions de CHF en deux tranches. Dans la première tranche, le capital social de la société sera augmenté de 60 065 750 CHF à 80 065 750 CHF par l’émission de 2 000 000 nouvelles actions nominatives d’une valeur nominale de 10 CHF chacune à un prix d’émission unitaire de 15 CHF. La période de souscription pour cette première tranche des augmentations de capital décidées s’est étendue du 30 novembre au 4 décembre 2020, à 12h00 (CET).Dans cette première tranche, un droit de souscription a été attribué pour chaque action MCH détenue après la clôture de la bourse le 27 novembre...

Announcement | MCH Group | Capital increase

Written by Customer Service on December 5, 2020. Posted in Public Companies.

Completion of the rights issue for the first tranche of the capital increasesOn 27 November 2020, the Extraordinary General Meeting of MCH Group Ltd. decided among other things to conduct capital increases of up to CHF 104.5 million in two tranches. In the first tranche, the company’s share capital is being increased from its current CHF 60,065,750 to CHF 80,065,750 through the issue of 2,000,000 new registered shares with a nominal value of CHF 10.00 for an issue price of CHF 15.00. The subscription period for this first tranche of the approved capital increases ran from 30 November to 12:00 noon (CET) on 4 December 2020.In this first tranche, one subscription right was allocated for each MCH share held after the close of trading on 27 November 2020. Three subscription rights entitled the holder to acquire one new share at a subscription...

Redwood Capital Management Limited: Stocks ended mixed lead by S&P 500 as it ekes out record high

Written by Customer Service on December 5, 2020. Posted in Public Companies.

Major Indices rallied on a great day in Wall Street and ended up mixed after positive reports with regards the new stimulus aids carries on after the US election and a rebound in crude oil’s price. Energy shares gains like Exxon Mobil Corp. and Chevron Corp. has contributed big time in S&P 500’s price in today’s trading session. Treasuries and Gold advances, dollar slumped. Meanwhile, below are the rest of the movements in Stock Market this Wednesday; Stocks • Nasdaq Composite dropped around 5.74 points or is 0.05% lower to 12,349.37.• S&P 500 rose with 6.56 points increased or is 0.18% higher to 3,669.01.• The Dow Jones Industrial Average surge about 61.12 points or is higher by 0.20% to 29,885.04.• The Stoxx Europe 600 Index is down by 0.1% to 391.69.• The MSCI All-Country World Index gained a bit with 0.3% increased to 626.59. Commodities •...

How To Apply For a Buy-To-Let Mortgage

Written by Customer Service on December 5, 2020. Posted in Public Companies.

There are many different types of buy-to-let mortgages available, such as interest-only buy-to-let mortgages to repayment mortgages. You may choose to purchase through a company, in which case you would need to take out a limited company buy-to-let mortgage. Mortgage availability and criteria also differs if you are based overseas, so your location should be considered before applying for certain mortgages. The first thing you may be wondering though, is what is a buy-to-let mortgage, and what is the difference between a buy-to-let mortgage and a residential mortgage? Buy-to-let mortgages vs. residential mortgages In truth, buy-to-let mortgages are not really that different from residential mortgages, but there are a few important things you would need to be aware of. When we talk about residential mortgages, we mean mortgages people take...

AMPORTS Expands Footprint With Acquisition of Horizon Terminals

Written by Customer Service on December 5, 2020. Posted in Mergers And Acquisitions.

JACKSONVILLE, Fla., Dec. 04, 2020 (GLOBE NEWSWIRE) — AMPORTS, Inc. (“AMPORTS”) today announced it has acquired a 100% equity interest in Horizon Terminal Services, LLC (“Horizon”), a marine terminal operator with operations in Jacksonville and Port Everglades, Florida, and Freeport, Texas, from Höegh Autoliners B.V. Based in Jacksonville, Florida, Horizon is a private marine terminal operator that provides customers with a variety of professional and value-added services, including vehicle and equipment processing, warehousing, long- and short-term storage, road and railroad access, and Foreign-Trade Zones. Notably, Horizon is equipped to manage a variety of cargoes, including high and heavy, static, breakbulk and project cargoes, as well as factory-new and previously-owned vehicles.“We are delighted to welcome Horizon to the AMPORTS...

Day: December 5, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice